Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The Company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Its product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
企業コードTEM
会社名Tempus AI Inc
上場日Jun 14, 2024
設立日2015
最高経営責任者「CEO」Mr. Eric P. Lefkofsky, J.D.
従業員数2400
証券種類Ordinary Share
決算期末Jun 14
本社所在地600 West Chicago Avenue
都市CHICAGO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号60654
電話番号18009765448
ウェブサイトhttps://www.tempus.com/
企業コードTEM
上場日Jun 14, 2024
設立日2015
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし